An analyst downgraded shares of biotechs Amgen and Celgene on Monday, saying both stocks are nearing appropriate values. Amgen stock ran up after a judge sided with it in a patent battle.

source https://finance.yahoo.com/m/45d7ec69-f45f-3660-9ee2-122ed1d8233b/why-the-2-biggest-biotech.html?.tsrc=rss